Rhythm Pharmaceuticals, Inc. (RYTM) News
Filter RYTM News Items
RYTM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RYTM News Highlights
- RYTM's 30 day story count now stands at 4.
- Over the past 2 days, the trend for RYTM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- RARE are the most mentioned tickers in articles about RYTM.
Latest RYTM News From Around the Web
Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.
Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns RemainNo summary available. |
Dosing underway in Rhythm Pharma''s setmelanotide trial for rare genetic disease of obesityRhythm Pharmaceuticals < |
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes ---- First patient also dosed in Phase 3 switch trial evaluating a weekly formulation of setmelanotide -- BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to tra |
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News . |
Zacks: Analysts Anticipate Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to Announce -$1.00 EPSWall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, [] |
Rhythm Pharmaceuticals (NASDAQ:RYTM) Research Coverage Started at Wells Fargo & CompanyWells Fargo & Company initiated coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) in a report issued on Wednesday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the stock. Morgan Stanley lowered shares of Rhythm Pharmaceuticals from [] |
Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ...Investment company Penn Series Small Cap Growth Fund (Current Portfolio) buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Rogers Corp, CarParts.com Inc, sells Guidewire Software Inc, Alarm.com Holdings Inc, Standex International Corp, H.B. |
Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have unfortunately lost 65% over the last yearTaking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Rhythm... |
Wells Fargo Bullish on These 2 Stocks for 90% Upside (Or More)Recent weeks have given us some hints that change may be in store. The Federal Reserve has indicated that it just may possibly be ready to start moving towards an end of its long-held easy money policy, and the Omicron variant of COVID is promising who-knows-what in the ongoing global health crisis. But the stock markets trending back up, after a late-November pullback. That turn upward would appear to have some historical backing. |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from BrokeragesShares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have received a consensus recommendation of Hold from the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 [] The post Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from Brokerages appeared first on ETF Daily News . |